APOL1-Mediated Kidney Disease

JAMA. 2024 May 21;331(19):1668-1669. doi: 10.1001/jama.2024.2667.
No abstract available

Plain language summary

This JAMA Insights reviews the origin of APOL1 high-risk genetic variants, defines APOL1-mediated kidney disease, and discusses recommendations for screening and management.

Publication types

  • Research Support, N.I.H., Extramural

MeSH terms

  • Africa South of the Sahara / epidemiology
  • Animals
  • Apolipoprotein L1* / genetics
  • Black People / genetics
  • Black People / statistics & numerical data
  • Black or African American* / genetics
  • Black or African American* / statistics & numerical data
  • Caribbean Region / epidemiology
  • Central America / epidemiology
  • Gene Frequency / genetics
  • Genetic Testing
  • Humans
  • Kidney Diseases / diagnosis
  • Kidney Diseases / epidemiology
  • Kidney Diseases / ethnology
  • Kidney Diseases / genetics
  • Mice
  • Renal Insufficiency, Chronic* / diagnosis
  • Renal Insufficiency, Chronic* / epidemiology
  • Renal Insufficiency, Chronic* / ethnology
  • Renal Insufficiency, Chronic* / genetics
  • South America / epidemiology
  • Trypanosomiasis, African* / epidemiology
  • Trypanosomiasis, African* / ethnology
  • Trypanosomiasis, African* / genetics
  • United States / epidemiology

Substances

  • APOL1 protein, human
  • Apolipoprotein L1